These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 24152194)

  • 1. Romiplostim in children with chronic immune thrombocytopenia (ITP): the French experience.
    Pasquet M; Aladjidi N; Guiton C; Courcoux MF; Munzer M; Auvrignon A; Lutz P; Ducassou S; Leroy G; Munzer C; Leverger G;
    Br J Haematol; 2014 Jan; 164(2):266-71. PubMed ID: 24152194
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Romiplostim therapy in children with unresponsive chronic immune thrombocytopenia.
    Mokhtar GM; Tantawy AA; El Sherif NH
    Platelets; 2012; 23(4):264-73. PubMed ID: 22471399
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of romiplostim for primary immune thrombocytopenia in children.
    Escudero Vilaplana V; Aragonés JH; Fernández-Llamazares CM; Bieler CB; Rodríguez SM; Sáez MS
    Pediatr Hematol Oncol; 2012 Mar; 29(2):197-205. PubMed ID: 22376020
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and efficacy of romiplostim in patients with eltrombopag-resistant or -intolerant immune thrombocytopenia.
    Tsukamoto S; Nakaseko C; Takeuchi M; Kumagai K; Komatsu T; Tanaka H; Hara S; Koizumi M; Imai H; Yokota A; Takeuchi M; Inokuchi K; Matsuura Y; Aotsuka N; Wakita H
    Br J Haematol; 2013 Oct; 163(2):286-9. PubMed ID: 23862773
    [No Abstract]   [Full Text] [Related]  

  • 5. Long-term use of the thrombopoietin-mimetic romiplostim in children with severe chronic immune thrombocytopenia (ITP).
    Bussel JB; Hsieh L; Buchanan GR; Stine K; Kalpatthi R; Gnarra DJ; Ho RH; Nie K; Eisen M
    Pediatr Blood Cancer; 2015 Feb; 62(2):208-213. PubMed ID: 25345874
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Successful treatment of Immune Thrombocytopenic Purpura (ITP) with the thrombopoietin-mimetic romiplostim.
    Meletis J; Katsandris A; Raptis SD; Mantzourani M
    Med Sci Monit; 2010 Aug; 16(8):CS100-2. PubMed ID: 20671616
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of self-administration of romiplostim by patients with chronic immune thrombocytopenia compared with administration by a healthcare provider.
    Selleslag D; Bird R; Altomare I; Giagounidis A; Janssens A; Pabinger I; Pullarkat V; Wei H; Kreuzbauer G
    Eur J Haematol; 2015 Feb; 94(2):169-76. PubMed ID: 25039799
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of a thrombopoietin receptor agonist on use of intravenous immune globulin in patients with immune thrombocytopenia.
    Zeller MP; Heddle NM; Kelton JG; Hamilton K; Wang G; Sholapur N; Carruthers J; Hsia C; Blais N; Toltl L; Hamm C; Pearson MA; Arnold DM
    Transfusion; 2016 Jan; 56(1):73-9. PubMed ID: 26400824
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Successful switching from eltrombopag to romiplostim in a pediatric patient with refractory chronic ITP].
    Mori M; Kato M; Koh K; Hanada R
    Rinsho Ketsueki; 2015 May; 56(5):511-3. PubMed ID: 26062675
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term treatment with romiplostim and treatment-free platelet responses in children with chronic immune thrombocytopenia.
    Tarantino MD; Bussel JB; Blanchette VS; Beam D; Roy J; Despotovic J; Raj A; Carpenter N; Mehta B; Eisen M
    Haematologica; 2019 Nov; 104(11):2283-2291. PubMed ID: 30846500
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Romiplostim in chronic immune thrombocytopenic purpura.
    Cersosimo RJ
    Clin Ther; 2009 Sep; 31(9):1887-907. PubMed ID: 19843480
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Romiplostim in children with chronic refractory ITP: randomized placebo controlled study.
    Elalfy MS; Abdelmaksoud AA; Eltonbary KY
    Ann Hematol; 2011 Nov; 90(11):1341-4. PubMed ID: 21318572
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The treatment for primary immune thrombocytopenia with romiplostim in adult and paediatric patients: use experience at a Spanish university hospital.
    Marquínez-Alonso I; Escudero-Vilaplana V; Pernía S; Beléndez Bieler C; Fernández-Llamazares CM; Sanjurjo-Sáez M
    J Clin Pharm Ther; 2014 Aug; 39(4):376-82. PubMed ID: 24702274
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical overview and practical considerations for optimizing romiplostim therapy in patients with immune thrombocytopenia.
    Kuter DJ; Tarantino MD; Lawrence T
    Blood Rev; 2021 Sep; 49():100811. PubMed ID: 33781612
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A large observational study of patients with primary immune thrombocytopenia receiving romiplostim in European clinical practice.
    Steurer M; Quittet P; Papadaki HA; Selleslag D; Viallard JF; Kaiafa G; Janssens A; Kozak T; Wadenvik H; Schoonen M; Belton L; Kreuzbauer G
    Eur J Haematol; 2017 Feb; 98(2):112-120. PubMed ID: 27557853
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Romiplostim treatment for children with immune thrombocytopenia: Results of an integrated database of five clinical trials.
    Tarantino MD; Despotovic J; Roy J; Grainger J; Cooper N; Beam D; Raj A; Maschan A; Kim J; Eisen M
    Pediatr Blood Cancer; 2020 Nov; 67(11):e28630. PubMed ID: 32902132
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Romiplostim in children with immune thrombocytopenia: a phase 3, randomised, double-blind, placebo-controlled study.
    Tarantino MD; Bussel JB; Blanchette VS; Despotovic J; Bennett C; Raj A; Williams B; Beam D; Morales J; Rose MJ; Carpenter N; Nie K; Eisen M
    Lancet; 2016 Jul; 388(10039):45-54. PubMed ID: 27103127
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of eltrombopag after romiplostim in primary immune thrombocytopenia.
    González-Porras JR; Mingot-Castellano ME; Andrade MM; Alonso R; Caparrós I; Arratibel MC; Fernández-Fuertes F; Cortti MJ; Pascual C; Sánchez-González B; Bernat S; Fuertes-Palacio MA; Vázquez-Paganini JA; Olivera PE; Alvarez-Román MT; Jarque I; Cortés M; Martínez-Robles V; Díaz-Gálvez FJ; Calbacho M; Fernández-Miñano C; Garcia-Frade J; González-López TJ
    Br J Haematol; 2015 Apr; 169(1):111-6. PubMed ID: 25521630
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pilot study of the effect of romiplostim on child health-related quality of life (HRQoL) and parental burden in immune thrombocytopenia (ITP).
    Klaassen RJ; Mathias SD; Buchanan G; Bussel J; Deuson R; Young NL; Collier A; Bomgaars L; Blanchette V
    Pediatr Blood Cancer; 2012 Mar; 58(3):395-8. PubMed ID: 21910213
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of Romiplostim during pregnancy as a rescue therapy in primary immune thrombocytopenia: Literature review and case description.
    Rosa María RN; Laura RL; Ángeles PB; Laura LB
    Platelets; 2020; 31(3):403-406. PubMed ID: 31116059
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.